FDA Accepts Application for Botox to Treat Masseter Muscle Prominence
If approved, the neurotoxin would be the first indicated for the temporary improvement of marked to very marked masseter muscle prominence in the United States.
If approved, the neurotoxin would be the first indicated for the temporary improvement of marked to very marked masseter muscle prominence in the United States.
The company is building a dedicated sales and medical affairs team to drive adoption of its neurotoxin and provide practices with direct clinical and commercial support.
Allergan Aesthetics’ Heidi Shurtz discusses updates to the APP loyalty program, including simplified savings, greater pricing transparency, and new benefits for growing aesthetics practices.